🇺🇸 FDA
Patent

US 8759006

PSCA: prostate stem cell antigen and distinguishing androgen receptor negative prostate cancer from benign prostatic hyperplasia

granted A61KA61K2039/505A61K31/704

Quick answer

US patent 8759006 (PSCA: prostate stem cell antigen and distinguishing androgen receptor negative prostate cancer from benign prostatic hyperplasia) held by The Regents of the University of California expires Mon Jun 19 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jun 24 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 19 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K2039/505, A61K31/704, A61K38/00, A61K39/395